Prostate Cancer, Stage IV Prostate Cancer
Conditions
Keywords
Prostate, Metastatic prostate cancer
Brief summary
The goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal therapy with docetaxel and LHRH analog would improve the outcome of high risk metastatic/stage IV prostate cancer.
Interventions
DRUGLuteinizing Hormone Releasing Hormone
During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
DRUGNew Hormonal Agent
During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
DRUGDocetaxel
During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel.
DRUGTislelizumab
During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
Sponsors
BeiGene
H. Lee Moffitt Cancer Center and Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy proven prostate cancer and the diagnosis can be established through either prostate biopsy or biopsy of a metastatic lesion. High risk mCSPC is defined as having 2 of the 3 risk factors: a Gleason score of 8 or more, at least 3 bone metastases, and the presence of measurable visceral metastasis. * ECOG performance status of 0-1 * No androgen deprivation therapy (ADT) with LHRH analogue monotherapy for more than 12 weeks after the diagnosis of metastatic prostate cancer. Prior ADT in the non-metastatic setting is allowed if it was given \> 2 years prior to the diagnosis of metastatic prostate cancer and a reduction of PSA is documented after initiating ADT in the metastatic setting. * Agreeable to prostate biopsy after completing second strike. * Adequate organ function with absolute neutrophil count \> 1000/l, Hb \> 10 g/dl, Platelet \> 100,000/l, Creatinine and liver enzymes within 1.5 folds of upper limits of normal * No uncontrolled arrhythmia; participants with h/o myocardial infarction or history of congestive heart failure, need to have estimated left ventricle ejection fraction above 40% either on echocardiogram or MUGA scan within 6 months of study enrollment. * All men who are sexually active with a female partner of childbearing potential treated or enrolled on this protocol must agree to use highly effective barrier contraception prior to the study, for the duration of study participation, and for 7 months after last dose of tislelizumab administration. * Ability to understand and the willingness to sign a written informed consent document or have a legally authorized representative sign on the participants behalf. Stated willingness to comply with all study procedures and availability for the duration of the study * \- Inclusion of minorities: Men of all races and ethnic groups who met the above inclusion criteria are eligible for this trial.
Exclusion criteria
* Prior treatments with TAK-700/Orteronel, abiraterone, darolutamide, apalutamide or enzalutamide for more than eight weeks. * Any previous treatment with a PD-1 or PD-L1 inhibitor * Documented brain metastases * Prior prostatectomy * History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel (including any drugs formulated with polysorbate 80), or LHRH analogue (e.g., leuprolide, triptorelin, goserelin acetate, degarelix) * Treatment with any investigational compound within 30 days prior to the first dose of study drugs * Diagnosis or treatment for another systemic malignancy within 2 years before the first dose of study drugs, or previously diagnosed with another malignancy & have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Participants with delayed healing of wounds, ulcers, and/or bone fractures * Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for tislelizumab to be less clinically active in this population. * Active or prior documented autoimmune or inflammatory disorders, including inflammatory bowel disease (e.g., Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, Grave's disease, rheumatoid arthritis, hypophysitis, uveitis, with the following exceptions: • Vitiligo or alopecia • Hypothyroidism stable on hormone replacement • Chronic skin condition that does not require systemic therapy • Celiac disease controlled by diet alone • Participants with inactive disease in the last 5 years may be included. * Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen \[HBsAg\]), or hepatitis C (HCV). Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Participants with positive HCV antibody are eligible if polymerase chain reaction is negative for HCV RNA. * Concurrent or prior use of immunosuppressive medication within 14 days before the first dose of study chemoimmunotherapy, with the following exceptions: premedication for docetaxel with 8 mg oral dexamethasone approximately 12 hr, 8 hr and 1 hr prior to each docetaxel administration; intranasal, inhaled, topical steroids, or local steroid injections (e.g., intraarticular injection); systemic corticosteroids at physiologic doses not exceeding 10mg/day of prednisone or its equivalent; steroids as premedication for hypersensitivity reactions (e.g., premedication for iodinated contrast allergy before CT scan) * History of severe hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc. * Was administered a live vaccine ≤ 4 weeks before first dose of tislelizumab NOTE:Seasonal vaccines for influenza and COVID-19 vaccines are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed. * Inability to comply with protocol requirements * Inclusion of minorities: Men of all races and ethnic groups who met the above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to 36 months | Overall survival will be from initiation of first strike until failure or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PSA <0.2 nanogram per milliliter (ng/ml) rate at 6 months | At 6 months | Investigators will measure the PSA \<0.2 nanogram per milliliter (ng/ml) at 6 months from the initiation of the first strike |
| PSA <0.2 nanogram per milliliter (ng/ml) rate at 12 months | At 12 months | Investigators will measure the PSA \<0.2 nanogram per milliliter (ng/ml) at 12 months from the initiation of the first strike |
| PSA Progression | Up to 36 months | Time to PSA progression from the initiation of first strike |
| Radiographic Progression | At 36 months | Investigators will measure the radiographic progression free survival rate at 36 months from the initiation of first strike |
| PSA <0.2 nanogram per milliliter (ng/ml) rate at 36 months | At 36 months | Investigators will measure the PSA \<0.2 nanogram per milliliter (ng/ml) at 36 months from the initiation of the first strike |
Other
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Standard Uptake Values (SUV) | Up to 9 months | Investigators will track the changes on F18 (Posluma or Pylarify) PSMA PET scan after first and second strikes compared to baseline. |
Countries
United States
Outcome results
None listed